scholarly journals Angiotensin receptor blocker telmisartan: efficacy, safety and relevance of clinical application

2017 ◽  
Vol 14 (1) ◽  
pp. 51-57
Author(s):  
M L Maksimov ◽  
O V Dralova
Keyword(s):  
Cardiovascular Disease ◽  
Metabolic Disorders ◽  
Angiotensin Receptor Blocker ◽  
Angiotensin Receptor Blockers ◽  
Pressure Control ◽  
Antihypertensive Efficacy ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Cardiovascular Morbidity And Mortality ◽  
Receptor Blockers

Angiotensin receptor blocker telmisartan is a modern and effective antihypertensive drug which has advantages in comparison with other drugs of the group of angiotensin receptor blockers. Long half-life retains its effect is significant more than 24 hours, which is especially important for blood pressure control in the dangerous morning hours. Telmisartan is excreted by the kidneys less than 2%, making its use safe in patients with renal pathology. High antihypertensive efficacy combined with its excellent tolerability. Telmisartan has the greatest affinity to PPARg-receptors, which is especially important when selecting antihypertensive therapy in patients with arterial hypertension and metabolic disorders, insulin resistance, metabolic disorders. A considerable number of studies showing the effectiveness of treatment with telmisartan in patients with cardiovascular disease, diabetes, metabolic syndrome, nephropathy. The article presents the results of a study of therapeutic equivalence of generic drug is telmisartan, which showed a high bioequivalence to original brand-name formulation and was according to the indications: hypertension and decrease cardiovascular morbidity and mortality in patients aged 55 years and older with a high risk of cardiovascular disease. The results of our observations show comparable antihypertensive efficacy of the original and generic products and well tolerated by the results of questioning of patients.

scholarly journals Azilsartan Medoxomil: Angiotensin Receptor Blocker in the Treatment of Hypertension

2018 ◽  
Vol 2 (1) ◽  
pp. 100
Author(s):  
Megha Sood ◽  
Jagminder Kaur Bajaj ◽  
Jagminder Kaur Bajaj
Keyword(s):  
Angiotensin Receptor Blocker ◽  
Angiotensin Receptor Blockers ◽  
Oral Treatment ◽  
Treatment Options ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Treatment Of Hypertension ◽  
Receptor Blockers ◽  
Artery Disease ◽  
Azilsartan Medoxomil

Hypertension is an important risk factor for cardiovascular and renal disease. It’s early detection and control is critically important as it is an important attributable cause of stroke, coronary artery disease, heart failure, atrial fibrillation and ESRD. Recent data indicates increasing prevalence of hypertension amongst various populations. This reflects the importance of having a variety of treatment options for the management of this condition. Angiotensin receptor blockers are highly effective at reducing blood pressure, have excellent tolerability and renoprotective properties, hence they remain a useful choice in the management of hypertension. Azilsartan medoxomil has recently been approved by the FDA for the oral treatment of hypertension making it the eighth Angiotensin receptor blocker to be approved for this indication.

Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore

Physiology ◽  
2021 ◽  
Vol 36 (3) ◽  
pp. 160-173 ◽  
Author(s):  
Juan M. Saavedra
Keyword(s):  
Blood Pressure ◽  
Immune Responses ◽  
Metabolic Disorders ◽  
Angiotensin Receptor Blockers ◽  
Pressure Control ◽  
Coagulation Cascade ◽  
Angiotensin Receptor ◽  
Age Related ◽  
Injury Mechanisms ◽  
Receptor Blockers

Beyond blood pressure control, angiotensin receptor blockers reduce common injury mechanisms, decreasing excessive inflammation and protecting endothelial and mitochondrial function, insulin sensitivity, the coagulation cascade, immune responses, cerebrovascular flow, and cognition, properties useful to treat inflammatory, age-related, neurodegenerative, and metabolic disorders of many organs including brain and lung.

Antihypertensive efficacy and safety of the angiotensin receptor blocker azilsartan in elderly patients with hypertension

2016 ◽  
Vol 40 (1) ◽  
pp. 110-114 ◽  
Author(s):  
Tomohito Kamada ◽  
Mutsuharu Hayashi ◽  
Wakaya Fujiwara ◽  
Daiji Yoshikawa ◽  
Daisuke Mukaide ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Angiotensin Receptor Blocker ◽  
Antihypertensive Efficacy ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Efficacy And Safety

scholarly journals Blood Pressure Control: Stroke and Stroke Prevention

2005 ◽  
Vol 6 (1_suppl) ◽  
pp. S8-S11
Author(s):  
Hans-Christoph Diener
Keyword(s):  
Blood Pressure ◽  
Stroke Prevention ◽  
Antihypertensive Drugs ◽  
Angiotensin Receptor Blockers ◽  
Antihypertensive Agents ◽  
Pressure Control ◽  
Angiotensin Receptor ◽  
Risk Of Death ◽  
Pressure Lowering ◽  
Receptor Blockers

Hypertension is the most important modifiable risk factor for primary and secondary stroke prevention. All antihypertensive drugs are effective in primary prevention: the risk reduction for stroke is 30—42%. However, not all classes of drugs have the same effects: there is some indication that angiotensin receptor blockers may be superior to other classes of antihypertensive drugs in stroke prevention. Seventy-five percent of patients who present to hospital with acute stroke have elevated blood pressure within the first 24—48 hours. Extremes of systolic blood pressure (SBP) increase the risk of death or dependency. The aim of treatment should be to achieve and maintain the SBP in the range 140—160 mmHg. However, fast and drastic blood pressure lowering can have adverse consequences. The PROGRESS trial of secondary prevention with perindopril + indapamide versus placebo + placebo showed a decrease in numbers of stroke recurrences in patients given both active antihypertensive agents, more impressive for cerebral haemorrhage.There were also indications that active treatment might decrease the development of post-stroke dementia.

Post-exercise Hypotension Produced by Supramaximal Interval Exercise is Potentiated by Angiotensin Receptor Blockers

2019 ◽  
Vol 40 (12) ◽  
pp. 756-761
Author(s):  
Miguel Ramirez-Jimenez ◽  
Felix Morales-Palomo ◽  
Juan Fernando Ortega ◽  
Ricardo Mora-Rodriguez
Keyword(s):  
Blood Pressure ◽  
Antihypertensive Medication ◽  
Angiotensin Receptor Blocker ◽  
Angiotensin Receptor Blockers ◽  
Blood Pressure Reduction ◽  
Angiotensin Receptor ◽  
Post Exercise ◽  
Interval Exercise ◽  
Receptor Blockers ◽  
Blood Pressure Responses

AbstractWe studied the effects of supramaximal interval exercise (SIE) with or without antihypertensive medication (AHM) on 21-hr blood pressure (BP) response. Twelve hypertensive patients chronically medicated with AHM, underwent three trials in a randomized order: a) control trial without exercise and substituting their AHM with a placebo (PLAC); b) placebo medicine and a morning bout of SIE (PLAC+SIE), and c) combining AHM and exercise (AHM+SIE). Acute and ambulatory blood pressure responses were measured for 21-hr after treatment. 20  min after treatment, systolic blood pressure (SBP) readings were reduced, similar to readings after PLAC+SIE (−9.7±6.0 mmHg, P<0.001) and AHM+SIE (−10.4±7.9 mmHg, P=0.001). 21 h after treatment, SBP remained reduced after PLAC+SIE (125±12 mmHg, P=0.022) and AHM+SIE (122±12 mmHg, P=0.013) compared to PLAC (132±16 mmHg). The BP reduction in PLAC+SIE faded out at 4 a.m., while in AHM+SIE it continued overnight. At night, BP reduction was larger in AHM+SIE than PLAC+SIE (–5.6±4.0 mmHg, P=0.006). Our data shows that a bout of supramaximal aerobic interval exercise in combination with ARB medication in the morning elicits a sustained blood pressure reduction lasting at least 21-h. Thus, the combination of exercise and angiotensin receptor blocker medication seems superior to exercise alone for acutely decreasing blood pressure.

The Evolving Role of Angiotensin Receptor Blockers in Heart Failure

2002 ◽  
Vol 37 (5) ◽  
pp. 474-482
Author(s):  
Patricia A. Howard
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Cardiovascular Pharmacotherapy ◽  
The Us ◽  
Prevention And Treatment ◽  
Recent Developments ◽  
Receptor Blockers

This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the US, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on the prevention and treatment of cardiovascular disease—if they keep current with developments in drug therapy.

Sign in / Sign up

Export Citation Format

Share Document